FDA advisers on Thursday voted against GSK's blood cancer drug Blenrep, finding that its risks outweighed its benefits at the ...

A setback for GSK after one of its late-stage pipeline assets failed to win the support of a US panel today triggered a 6% ...

The FDA has approved GSK's Shingrix vaccine (recombinant zoster vaccine or RZV) in a prefilled syringe presentation to prevent shingles.

Investing.com -- GSK (LON: GSK) shares dropped more than 6% on Friday after a U.S. Food and Drug Administration advisory panel voted against the benefit-risk profile of Blenrep (belantamab ...

GSK was the standout laggard on the FTSE 100, sinking 6.2% after a US Food & Drug Administration advisory panel voted against approving its cancer drug Blenrep at the proposed dosage. Although the FDA ...

(Alliance News) - Stock prices in Europe opened higher early on Friday, with the FTSE 100 almost hitting a new record high, as a swathe of dealmaking was well-received in London. The FTSE 100 index ...

U.S. futures for the S&P 500 were up 0.1% and futures for the Dow Jones Industrial Average rose 0.2%. Changes in futures do not necessarily predict movements after the opening bell.

GSK shares fell more than 6% on Friday to the bottom of Britain's blue-chip index after a U.S. FDA advisory panel recommended ...

The British drugmaker was trying to revive the drug, which was pulled from U.S. markets in 2022 after failing a late-stage ...

GSK Plc shares tumbled after its blood cancer drug failed to secure the backing of a panel of US regulatory advisers, putting ...

Finance News; Setback for GSK as Blenrep does not win US FDA committee support; Setback for GSK as Blenrep does not win US FDA committee support ...

Mistral added deep research capabilities to its Le Chat platform, bringing it in direct competition against ChatGPT and ...